 Patients receive obinutuzumab intravenously IV on day 1 days 1, 2, 8, and 15 for course 1 only every 28 days for up to 8 courses. Beginning in course 2, patients receive ibrutinib orally PO once daily QD on days 1-28. Beginning in course 3, patients receive Bcl-2 inhibitor GDC-0199 PO QD on days 1-28. Treatment repeats every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity. 